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Abstract
A 34 year old woman diagnosed with breast cancer and liver metastases underwent a left subclavian
Portacath insertion. During the procedure, the clinical features and the findings of intra-operative
investigations provided conflicting evidence of the catheter position. This report highlights the
potential difficulties in establishing long-term central venous access, the limitations of common
investigations and safety issues relating to the process of subclavian line insertion.
Background
Portacaths (Bard Medical Division, Georgia, USA) are rou-
tinely used for central venous access in patients with poor
peripheral veins who require chemotherapy, either in the
adjuvant or metastatic disease setting. The technique pro-
vides a permanent, closed venous system with easy vascu-
lar access for drug delivery and blood draw that is more
discrete and convenient than Hickmann lines and periph-
erally inserted central catheters (PICC), where part of the
system lies ex-vivo. We present a case report that high-
lights potential difficulties in identifying the catheter posi-
tion and consider the limitations of common methods of
confirming the catheter location.
Case presentation
A woman was aged 34 years when she presented with a T2
G2 N0 right breast cancer that was ER negative, PgR nega-
tive and HER-2 3+. She was otherwise well with no family
history of cancer. She was started on 5 fluorouracil, epiru-
bicin and cyclophosphamide (FEC) chemotherapy with
gosarelin (Zoladex) and recombinant human granulo-
cyte-colony stimulating factor, G-CSF, (Filgrastim) sup-
port. Prior to starting trastuzumab (Herceptin), a MUGA
scan was performed showing a normal resting gated left
ventricular ejection fraction of 57% and a normal size left
ventricle. As she described increasing shortness of breath
over the proceeding 6 months, a CT scan was done which
showed no abnormality in the lung parenchyma but sev-
eral scattered metastases were identified within the liver
varying in size up to 3.5 cm with the largest lesion in seg-
ment 6.
With minimal response to chemotherapy, she proceeded
to transarterial hepatic chemo-embolisation with mito-
mycin C/gemcitabine and converted to docetaxel (Taxo-
tere) after 2 cycles of FEC. She was referred for Portocath
insertion after 3 cycles of 2 weekly docetaxel for her ongo-
ing taxane/trastuzumab chemotherapy. Her haemoglobin
fell to 8.5 g/dL following chemotherapy at the time of Por-
tocath insertion.
A left subclavian approach using the landmark technique
was chosen. The vein was cannulated at first pass. The col-
our of the aspirated blood was bright red and there was
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brisk, pulsatile backflow through the needle. As the guide
wire appeared to be appropriately placed in the right
atrium on the image intensifier, the procedure continued
with dilation of the vein and insertion of the catheter. The
per-operative catheter position was indeterminate on
image intensifier screening. The patient was being venti-
lated with 100% oxygen (FiO2 = 1). A catheter blood sam-
ple revealed a PO2 of 16.7 kPa, PCO2 of 6.45 with a PH
of 7.28. As the PO2 could still be compatible with an arte-
rial sample, Ultravist 300 (Lopromide) (Schering, West
Sussex, UK) was injected down the catheter but the con-
trast dissipated so rapidly that the screening images were
unhelpful in distinguishing arterial from venous catheter-
isation. Pulsatile blood flow continued despite holding
the catheter 20cm above the patient's chest. Manometry
was therefore used to provide objective pressure readings.
The initial reading of 55/6 mmHg was interpreted to be in
the right ventricle and drawing the catheter back with
screening measured the superior vena cava pressure to be
22/4 mmHg. The arterial blood pressure at the time was
105/70 mmHg. We were thus finally convinced of the true
catheter position based on the anatomical images and the
physiological pressure readings. Appropriate catheter
position was confirmed on the post-procedure chest X-
ray.
Discussion
Difficulty in identifying the catheter position occurs occa-
sionally and this report illustrates commonly used proce-
dures to establish the true location of the catheter. This
case demonstrates that none of these methods are individ-
ually reliable because of variation in anatomy or altered
physiology from disease or its treatment. In our case, as
the procedure was performed under a general anaesthetic
in the operating theatre, we had full control of the situa-
tion with readily available equipment and monitoring.
We were able to confirm the catheter position without
unnecessary withdrawal and re-cannulation of the vessel,
thus avoiding the risk of inadvertent iatrogenic injuries.
In breast cancer, anthracycline chemotherapy and trastu-
zumab are frequently used and in combination can pre-
dispose to cardiac failure. The presence of significant liver
metastases could increase the venous pressure and anae-
mia further predisposes to a hyperdynamic circulation. An
increase in the number of requests for long term venous
catherisation can be anticipated in patients who are on
chemotherapy and biological treatment such as trastuzu-
mab. Procedures to establish long term central venous
catheterisation may be carried out in a variety of hospital
locations depending on local practice including wards
and radiology departments where access to monitoring
may be less available. When difficulties are encountered,
the complications can be distressing to patients. Operat-
ing theatres and radiological vascular intervention suites
are well equipped for this purpose.
Hind et al performed a meta-analysis reviewing the use of
ultrasound for central venous catheter placement and
advocated the routine use of two dimensional ultrasonog-
raphy [1]. The case for the use of ultrasound was stronger
for internal jugular vein catheterisation compared with
cannulation of the subclavian or femoral veins. The
National Institute of Clinical Excellence guidance also
advocates the use of ultrasound for internal jugular vein
placement [2]. The overall safety of permanent venous
devices and acceptable long-term complications was
reviewed in a retrospective study of 1422 procedures by
Sariego et al [3]. In our case, access to the subclavian vein
was not the issue but uncertainty about the position of the
catheter once line access had been established was the
cause of consternation. We usually use the landmark tech-
nique for subclavian vein cannulation but have access to
per-operative ultrasound in the operating theatre should
there be difficulty in obtaining venous access which was
not the case in this patient.
Crozier et al (2006) reviewed the landmark technique
with experienced operators. The complication rates were
low, affecting only 14 of 201 patients (7%) over a five year
period [4]. Gopal et al (2006) evaluated the success and
complication rate of nurse-led subclavian central venous
catheter insertion using the landmark technique over a six
month period [5]. Complications occurred in 48 out of
348 lines (14%), including catheter malposition, arterial
puncture and pneumothorax, with an overall procedure
failure rate of 1%. While nurse-led subclavian vein cannu-
lation using the landmark technique was both safe and
effective, the complication rates were twice that of an
experienced medical operator.
Gualtieri et al reported the results of a randomized study
in 1996 comparing subclavian venous catheterization by
operators of variable experience [6]. They compared the
success rate of using the landmark technique with ultra-
sound guidance, and found that ultrasound guidance
improved the success rate of catheterization by less expe-
rienced operators. Ultrasound facility should be routinely
available during the cannulation procedure at least as an
adjunct to line placement.
Conclusion
A complete understanding of the anatomy and physiology
is an essential part of safe line placement. The placement
of in-dwelling central venous catheters should be by ded-
icated teams within the hospital. Appropriate monitoring
should be available for all patients by a trained clinician
such as an experienced anaesthetist, separate from the
practitioner inserting the catheter. Whilst there is anPublish with BioMed Central    and   every 
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increasing tendency for central line placement to be
devolved to nurse practitioners, we urge caution about the
delegation of such responsibility without rigorous proto-
cols on action in the event of difficulty.
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